BridgeBio Pharma, Inc.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(538,303) | $(275,958) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 98,385 | 65,673 |
| Loss on extinguishments of debt | 21,155 | 26,590 |
| Noncash interest expense on deferred royalty obligations (1) | 86,460 | — |
| Amortization of debt discount and issuance costs | 4,515 | 5,399 |
| Depreciation and amortization | 3,999 | 4,708 |
| Noncash lease expense | 3,443 | 3,119 |
| Net loss from equity method investments | 51,579 | 14,488 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | (11,062) | — |
| Noncash income from an equity method investment | (7,769) | — |
| Gain on deconsolidation of subsidiaries | — | (178,321) |
| Gain from investment in equity securities, net | — | (8,136) |
| Other noncash adjustments, net | (1,217) | (2,059) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (111,796) | 1,273 |
| Inventories | (23,356) | — |
| Prepaid expenses and other current assets | (17,527) | (17,543) |
| Other assets | 568 | (428) |
| Accounts payable | 9,084 | 5,257 |
| Accrued compensation and benefits | 3,212 | 5,580 |
| Accrued research and development liabilities | 347 | 15,454 |
| Operating lease liabilities | (4,757) | (4,459) |
| Deferred revenue | (9,480) | 20,575 |
| Other liabilities (2) | 53,030 | (6,612) |
| Net cash used in operating activities | (389,490) | (325,400) |
| Investing activities: | ||
| Purchases of marketable securities | (10,876) | (93,811) |
| Maturities of marketable securities | 8,000 | 95,000 |
| Purchases of investments in equity securities | — | (20,271) |
| Proceeds from sales of investments in equity securities | — | 63,229 |
| Proceeds from special cash dividends received from an investment in equity securities | 2,302 | 25,682 |
| Payment for intangible assets | (8,495) | (4,785) |
| Purchases of property and equipment | (1,064) | (886) |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | — | (140) |
| Net cash provided by (used in) investing activities | (10,133) | 64,018 |
| Financing activities: | ||
| Proceeds from issuance of 2031 Notes | 575,000 | — |
| Issuance costs and discounts associated with 2031 Notes | (12,034) | — |
| Repurchase of common stock | (48,276) | — |
| Proceeds from a royalty obligation under the Royalty Purchase Agreement | 300,000 | — |
| Issuance costs associated with a royalty obligation under the Royalty Purchase Agreement | (3,010) | — |
| Proceeds from term loan under the Amended Financing Agreement | — | 450,000 |
| Issuance costs and discounts associated with term loan under the Amended Financing Agreement | — | (15,986) |
| Repayment of term loans | (459,000) | (473,417) |
| Repayments of deferred royalty obligations (3) | (6,896) | — |
| Proceeds from issuance of common stock through public offerings, net | — | 314,741 |
| Proceeds from common stock issuances under ESPP | 6,414 | 4,502 |
| Proceeds from stock option exercises, net of repurchases | 14,523 | 808 |
| Transactions with noncontrolling interests | 1,550 | — |
| Repurchase of RSU shares to satisfy tax withholding | (6,796) | (6,122) |
| Net cash provided by financing activities | 361,475 | 274,526 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (38,148) | 13,144 |
| Cash, cash equivalents and restricted cash at beginning of period | 683,244 | 394,732 |
| Cash, cash equivalents and restricted cash at end of period | $645,096 | $407,876 |
(1)Including a related party amount of $5,560 for the nine months ended September 30, 2025 (as described in Note 10).
(2)Including a related party amount of $1,647 for the nine months ended September 30, 2025 (as described in Note 10).
(3)Including a related party amount of $(665) for the nine months ended September 30, 2025 (as described in Note 10).
Condensed Consolidated Statements of Cash Flows
(Continued)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $43,670 | $78,236 |
| Cash paid for income taxes | $1,153 | $— |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Unpaid property and equipment | $12 | $274 |
| Transfers to noncontrolling interests | $(4,734) | $(4,719) |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $642,951 | $266,324 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 126 | 139,409 |
| Restricted cash — Included in “Other assets” | 2,019 | 2,143 |
| Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows | $645,096 | $407,876 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.